AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 33 min read$WAT

Waters Corp (WAT) Q3 2026 Earnings Call Highlights: Raised Guidance, 21% EPS Growth

Waters Corp (WAT) reported Q3 2026 revenue growth of 10% and raised full-year guidance. Adjusted EPS grew 21% to $4.10. New products and acquisitions drove growth, while China and inventory levels posed challenges. The company expects mid-single-digit growth in 2027, with AI and pricing as upside levers.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Waters Corp (WAT) Q3 2026 Earnings Call Highlights: Raised Guidance, 21% EPS Growth — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$WATBullishHigh
01

Why it matters

The guidance lift and EPS beat are likely to trigger buying interest, especially from investors in the life‑science tools sector.

02

Market read

Waters' earnings beat and guidance raise provide a fresh catalyst for the stock, making it a near‑term trading opportunity.

03

What to watch

Potential headwinds from China DRG policy and the $81 M integration expense could dampen near‑term cash flow.

Relevance 8/10Novelty 8/10Timing: today

Background

Waters Corp released its Q3 2026 earnings call transcript, highlighting revenue growth, product launches, and raised guidance.

Company-level read

Ticker impact

$WATBullishHigh confidence
Context

Waters Corp raised full-year 2026 organic revenue guidance to 9.1%-9.7% and reported 21% EPS growth in Q3 2026.

Expected impact

likely upward as investors price in higher revenue and earnings expectations

Evidence & confidence

The company delivered 10% organic revenue growth, beat EPS expectations, and lifted guidance, which typically drives buying pressure.

Market effects

Sector

Positive for life‑science instrumentation and analytical chemistry sector as Waters' growth signals demand for flow cytometry and mass spectrometry tools.

Regional

Neutral to positive for U.S. biotech equipment market; modest impact on China exposure due to improving local manufacturing.

Global

Modest, limited to investors focused on analytical instruments and biotech supply chain.

Counterpoint

What could challenge this read

If integration costs and inventory buildup persist, the guidance may be overly optimistic and could lead to a pull‑back.

Key entities

  • Executive
    Udit Batra

    CEO of Waters Corp who discussed growth outlook and AI initiatives.

  • Executive
    Amol Chaubal

    CFO of Waters Corp who explained margin framework and cost synergies.

Read at source← All news

StoryWaters Corp. posts Q3 2026 revenue of $1.767 B, raises full‑year guidance and announces MOBILion acquisition

Also covered by

4 outlets

Related articles

NOV 4
$WATHighAI 8/10

Bernstein raises Waters stock price target to $535 on earnings beat

Bernstein raised its price target on Waters Corp. (WAT) to $535 from $450, citing strong Q3 2026 results. Revenue grew 10% in constant currency, and adjusted EPS of $4.10 beat estimates. The company raised full-year 2026 guidance for revenue and EPS. Bernstein described the 2027 outlook as conservative, with mid-single-digit-plus organic growth expected. Other analysts also raised price targets following the earnings beat.

investing.com2 min
NOV 4
$WATMed

KeyBanc raises Waters stock price target to $500 on guidance boost

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

investing.com2 min
NOV 4
$WATMedAI 8/10

Waters Q3 Earnings Call Highlights

Waters Corporation (WAT) reported Q3 revenue of $575M in Advanced Diagnostics, up 2%, and $500M in Diagnostic Solutions, flat. Microbiology revenue grew 4% outside China but declined 20% in China. Clinical Business Unit revenue rose 17%, and Materials Sciences revenue increased 7%. The company expects to recover revenue from reagent-rental compliance and announced partnerships for its Onclarity HPV kit.

finance.yahoo.com2 min